Alemtuzumab gets a license in Chile

Is early, effective, induction therapy the new treatment paradigm for MS? #MSBlog #MSResearch

"As promised the following are my slides from yesterday's talk at the SINS meeting in Santiago, Chile. I was asked to talk on alemtuzumab as it has just been given a license in Chile with the same broad indication as that in Europe. Most of the Chilean MSologists I spoke to have a lot of experience using rituximab off-license so I don't see any problems them using alemtuzumab in their current clinical practice."



CoI: multiple

Labels: , ,